| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8789921 | Urologic Oncology: Seminars and Original Investigations | 2018 | 6 Pages |
Abstract
Significant under-representation was observed for elderly and Hispanic patients with a trend toward under-representation for black and female patients in phase I to II RCC clinical trials. Greater efforts to include underrepresented populations are necessary to improve the effectiveness and generalizability of clinical trials in kidney cancer.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Alain B.S., Kyle A. M.D., David J. M.Sc., Alp Tuna M.D., Isuru M.D., John P. M.D., Ketan K. M.D.,